Andrea Necchi1, Salvatore Lo Vullo2, Luigi Mariani2, Daniele Raggi3, Patrizia Giannatempo3, Giuseppina Calareso4, Elena Togliardi5, Flavio Crippa6, Nicola Di Genova7, Federica Perrone8, Maurizio Colecchia8, Biagio Paolini8, Giuseppe Pelosi8,9, Nicola Nicolai10, Giuseppe Procopio3, Roberto Salvioni10, Filippo G De Braud3,9. 1. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milano, Italy. andrea.necchi@istitutotumori.mi.it. 2. Clinical Epidemiology and Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 3. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milano, Italy. 4. Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 5. Pharmacy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 6. Nuclear Medicine and PET Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 7. Clinical Trials Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 8. Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 9. Università degli Studi di Milano, Milano, Italy. 10. Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Abstract
BACKGROUND: Progress in developing effective salvage therapies for UC is warranted. Alisertib is an orally available, selective inhibitor of the aurora kinase A. METHODS: A single-group, phase 2 trial was conducted with alisertib 50 mg orally BID for 7 days, with 14d rest until disease progression (PD) (NCT02109328). The primary endpoint (EP) was RECIST 1.1 objective response-rate (ORR, H0 ≤ 5%, H1 ≥ 20%, α = 10% and β = 20%). Eligibility included failure of at least one platinum-based regimen. RESULTS: From 10/2014 to 04/2015, 22 patients were enrolled (20 evaluable for response), 8 (36.4%) in second-line and 14 (63.6 %) beyond the second-line. Eight (36.4%) had an ECOG-performance status 1-2. Two partial responses (PR, ORR: 9.1%), 7 stable disease (SD) and 11 PD were obtained. Median follow-up was 8.3 months (IQR: 7-10.3), 6-month progression-free survival (PFS) was 13.6% (95%CI: 4.8-39.0). Two SD are still receiving treatment after 11.5 and 6.3 months. Median overall survival (OS) was not reached (6-month OS: 59.1%, 95%CI: 41.7-83.7). Hb < 10 g/dl was significantly associated with shorter PFS and OS multivariably (p = 0.031 and p = 0.033). Tissue of the case with 11.5 month SD harbored a missense mutation of mTOR (E1813D), the nonsense mutation Q527STOP of TSC1, HER3 and TAF1L missense mutations. Grade 3-4 adverse events (AE) were: 40.9% mucositis, 36.4% fatigue, 18.2% neutropenia (13.6% febrile neutropenia). There were 2 treatment-related deaths. CONCLUSIONS: The study did not meet the primary EP, yet sustained disease control was obtained in about 14% of patients. The incidence of AE and the issue of patient selection are two major concerns.
BACKGROUND: Progress in developing effective salvage therapies for UC is warranted. Alisertib is an orally available, selective inhibitor of the aurora kinase A. METHODS: A single-group, phase 2 trial was conducted with alisertib 50 mg orally BID for 7 days, with 14d rest until disease progression (PD) (NCT02109328). The primary endpoint (EP) was RECIST 1.1 objective response-rate (ORR, H0 ≤ 5%, H1 ≥ 20%, α = 10% and β = 20%). Eligibility included failure of at least one platinum-based regimen. RESULTS: From 10/2014 to 04/2015, 22 patients were enrolled (20 evaluable for response), 8 (36.4%) in second-line and 14 (63.6 %) beyond the second-line. Eight (36.4%) had an ECOG-performance status 1-2. Two partial responses (PR, ORR: 9.1%), 7 stable disease (SD) and 11 PD were obtained. Median follow-up was 8.3 months (IQR: 7-10.3), 6-month progression-free survival (PFS) was 13.6% (95%CI: 4.8-39.0). Two SD are still receiving treatment after 11.5 and 6.3 months. Median overall survival (OS) was not reached (6-month OS: 59.1%, 95%CI: 41.7-83.7). Hb < 10 g/dl was significantly associated with shorter PFS and OS multivariably (p = 0.031 and p = 0.033). Tissue of the case with 11.5 month SD harbored a missense mutation of mTOR (E1813D), the nonsense mutation Q527STOP of TSC1, HER3 and TAF1L missense mutations. Grade 3-4 adverse events (AE) were: 40.9% mucositis, 36.4% fatigue, 18.2% neutropenia (13.6% febrile neutropenia). There were 2 treatment-related deaths. CONCLUSIONS: The study did not meet the primary EP, yet sustained disease control was obtained in about 14% of patients. The incidence of AE and the issue of patient selection are two major concerns.
Authors: Guru Sonpavde; Gregory R Pond; Jonathan E Rosenberg; Dean F Bajorin; Toni K Choueiri; Andrea Necchi; Giuseppe Di Lorenzo; Joaquim Bellmunt Journal: J Urol Date: 2015-08-17 Impact factor: 7.450
Authors: Walter M Stadler; David J Vaughn; Guru Sonpavde; Nicholas J Vogelzang; Scott T Tagawa; Daniel P Petrylak; Peter Rosen; Chia-Chi Lin; John Mahoney; Sanjiv Modi; Peter Lee; Marc S Ernstoff; Wu-Chou Su; Alexander Spira; Korinna Pilz; Richard Vinisko; Charles Schloss; Holger Fritsch; Charles Zhao; Michael A Carducci Journal: Cancer Date: 2013-12-11 Impact factor: 6.860
Authors: Joaquim Bellmunt; Toni K Choueiri; Ronan Fougeray; Fabio A B Schutz; Yacine Salhi; Eric Winquist; Stéphane Culine; Hans von der Maase; David J Vaughn; Jonathan E Rosenberg Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price Journal: Eur J Cancer Date: 1999-12 Impact factor: 9.162
Authors: Andres Cervantes; Elena Elez; Desamparados Roda; Jeffrey Ecsedy; Teresa Macarulla; Karthik Venkatakrishnan; Susana Roselló; Jordi Andreu; Jungah Jung; Juan Manuel Sanchis-Garcia; Adelaida Piera; Inma Blasco; Laura Maños; José-Alejandro Pérez-Fidalgo; Howard Fingert; Jose Baselga; Josep Tabernero Journal: Clin Cancer Res Date: 2012-07-02 Impact factor: 12.531
Authors: Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Guru Sonpavde; Gregory R Pond; Toni K Choueiri; Stephanie Mullane; Guenter Niegisch; Peter Albers; Andrea Necchi; Giuseppe Di Lorenzo; Carlo Buonerba; Antonio Rozzi; Kazumasa Matsumoto; Jae-Lyun Lee; Hiroshi Kitamura; Haruki Kume; Joaquim Bellmunt Journal: Eur Urol Date: 2015-08-08 Impact factor: 20.096
Authors: Nikhil Wagle; Brian C Grabiner; Eliezer M Van Allen; Eran Hodis; Susanna Jacobus; Jeffrey G Supko; Michelle Stewart; Toni K Choueiri; Leena Gandhi; James M Cleary; Aymen A Elfiky; Mary Ellen Taplin; Edward C Stack; Sabina Signoretti; Massimo Loda; Geoffrey I Shapiro; David M Sabatini; Eric S Lander; Stacey B Gabriel; Philip W Kantoff; Levi A Garraway; Jonathan E Rosenberg Journal: Cancer Discov Date: 2014-03-13 Impact factor: 39.397
Authors: Xiwei Ding; Tianlu Huang; Chunyan Peng; Keun Soo Ahn; Jesper B Andersen; Monika Lewinska; Yu Cao; Guifang Xu; Gang Chen; Bo Kong; Helmut Friess; Shanshan Shen; Lewis R Roberts; Lei Wang; Xiaoping Zou Journal: J Cancer Date: 2020-02-03 Impact factor: 4.207
Authors: Earle F Burgess; Chad Livasy; Sally Trufan; Jason Zhu; Hazel F O'Connor; Aaron Hartman; Peter E Clark; Claud Grigg; Derek Raghavan Journal: Mol Clin Oncol Date: 2022-04-08
Authors: Agnieszka Latosinska; Marika Mokou; Manousos Makridakis; William Mullen; Jerome Zoidakis; Vasiliki Lygirou; Maria Frantzi; Ioannis Katafigiotis; Konstantinos Stravodimos; Marie C Hupe; Maciej Dobrzynski; Walter Kolch; Axel S Merseburger; Harald Mischak; Maria G Roubelakis; Antonia Vlahou Journal: Oncotarget Date: 2017-04-20
Authors: Jianwen Hao; Qizhen Peng; Keruo Wang; Ge Yu; Yi Pan; Xiaoling Du; Na Hu; Xuening Zhang; Yu Qin; Huikai Li Journal: Biomed Res Int Date: 2021-07-22 Impact factor: 3.411